PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.
复制标题
PD-1，PD-L1（B7-H1）和肿瘤部位免疫调节疗法：历史观点。
DOI：
10.1186/s13045-017-0403-5
复制
发表时间：
2017-01-25
影响因子：
28.5
通讯作者：
Li Z
中科院分区：
文献类型：
--
作者：
Wang J;Yuan R;Song W;Sun J;Liu D;Li Z
目前针对细胞毒性T淋巴细胞相关蛋白4（CTLA-4）和程序性死亡1/程序性死亡配体1（PD-1/PD-L1，本文统称为PD）途径的靶向抑制的成功被誉为癌症免疫治疗的突破。PD-L1也被称为B7同系物1（B7-H1），最初由陈列平博士于1999年发现。为了表彰陈博士对PD导向治疗癌症的发展所做出的开创性贡献，美国华人血液学家和肿瘤学家网络（CAHON）决定在CAHON 2015年年会上授予他首届血液学和肿瘤学终身成就奖。这篇文章记录了陈在免疫肿瘤学领域的重要发现，这些发现超越了他最初的决定性发现。它还认为，PD导向治疗应被适当地视为肿瘤部位免疫调节治疗，以区别于基于CTLA-4的免疫检查点阻断剂。
The current success of targeted inhibition against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death 1/Programmed Death Ligand 1 (PD-1/PD-L1, herein collectively referred to as PD) pathways is hailed as a cancer immunotherapy breakthrough. PD-L1, known also as B7 homolog 1 (B7-H1), was initially discovered by Dr. Lieping Chen in 1999. To recognize the seminal contributions by Chen to the development of PD-directed therapy against cancer, the Chinese American Hematologist and Oncologist Network (CAHON) decided to honor him with its inaugural Lifetime Achievement Award in Hematology and Oncology at the CAHON’s 2015 annual meeting. This essay chronicles the important discoveries made by Chen in the exciting field of immuno-oncology, which goes beyond his original fateful finding. It also argues that PD-directed therapy should be appropriately considered as Tumor-Site Immune Modulation Therapy to distinguish it from CTLA-4-based immune checkpoint blocking agents.